The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.